III

Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control

Retrieved on: 
Tuesday, May 30, 2023
MAKE, ACT, AS, UPON, FOR, TAX, OF, NO, PAST, ITS, TIME, EACH, DATE, FINANCIAL, FUTURE, AND, IT, III, BY, NOT, UPDATE, ALL, THIS, SET, USE, FCA, EUROPEAN UNION, AWARE, EXPRESS, IS, ANY, FAIR, Medical device, Audit, EU

SUBJECT TO THE FOREGOING, AND AS SET FORTH BELOW, DR. MILNER INTENDS TO MAKE AVAILABLE AT AN APPROPRIATE TIME ADDITIONAL INFORMATION ABOUT THE EXTRAORDINARY GENERAL MEETING INCLUDING HOW TO VOTE AT SUCH MEETING.

Key Points: 
  • SUBJECT TO THE FOREGOING, AND AS SET FORTH BELOW, DR. MILNER INTENDS TO MAKE AVAILABLE AT AN APPROPRIATE TIME ADDITIONAL INFORMATION ABOUT THE EXTRAORDINARY GENERAL MEETING INCLUDING HOW TO VOTE AT SUCH MEETING.
  • DR. MILNER HAS INVESTMENTS IN ABCAM PLC (THE “COMPANY”), AND CONSEQUENTLY HAS A FINANCIAL INTEREST IN THE PROFITABILITY OF HIS POSITIONS IN THE COMPANY.
  • DR. MILNER IS NOT RESPONSIBLE TO ANY PERSON FOR PROVIDING ADVICE IN RELATION TO THE SUBJECT MATTER OF THIS DOCUMENT.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Global Rare Disease Clinical Trials Market Report 2023: Sector is Expected to Reach $24.25 Billion by 2030 at a CAGR of 9.7% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 31, 2023
Pharmaceutical, Health, Clinical Trials, Orphan Drug Act of 1983, Volunteering, Allergy, Health Research Board, Infection, Research, USD, Bangladesh Technical Education Board, Organization, Cancer, Growth, Rare, III, NIH, Disease, Pharmaceutical industry

Government initiatives that encourage product development, such as the Orphan Drug Act, are further expected to assist industry growth.

Key Points: 
  • Government initiatives that encourage product development, such as the Orphan Drug Act, are further expected to assist industry growth.
  • According to the National Institutes of Health (NIH), there are more than 7,000 rare diseases worldwide.
  • The growing awareness among people regarding rare diseases and growing interest in developing potential treatments for treating rare diseases are expected to support market growth.
  • For instance, in February 2022, the Health Research Board funded USD 1.1 million to support rare disease clinical trials.

Lovett Industrial Announces Two Build-To-Suit Industrial Buildings Totaling 960,956 Square Feet Inside the Largest Business Park Under Development in Infill Dallas, Texas

Retrieved on: 
Tuesday, May 30, 2023
REIT, Building Systems, Other Construction & Property, Commercial Building & Real Estate, Construction & Property, Heart, Arch-Con Corporation, Trinity Medical Center, Texas State Highway Loop 12, Multimedia, CBRE, Building, I-35, Industrial, III, Warehouse, Self storage

The buildings are part of the larger Trinity West Business Park development in Dallas, Texas located at the northwest corner of Singleton Boulevard and Norwich Street.

Key Points: 
  • The buildings are part of the larger Trinity West Business Park development in Dallas, Texas located at the northwest corner of Singleton Boulevard and Norwich Street.
  • (Photo: Business Wire)
    Colby Everett, Director at Lovett Industrial, commented, “Lovett Industrial is grateful for the opportunity to develop Buildings II and III at Trinity West on a build-to-suit basis.
  • Upon completion Trinity West Business Park will consist of three buildings totaling just under two million square feet.
  • Lovett Industrial currently is active in 6 additional markets across the U.S. and has approximately 7 million square feet under construction companywide.

Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023
Abstract, Male, Bevacizumab, Progression-free survival, Platelet, DCR, Overalls, Survival, RECIST, OS, Trae tha Truth, Multimedia, Poster session, Transfection, Immunotherapy, Carboplatin, Antibody, PFS, ASCO, American Society of Clinical Oncology, Proteinuria, ORR, Incidence, Etoposide, ECOG, HCC, PD-1, Smoking, III, Society, SD, Vaccine, Pharmaceutical industry, Part, Safety, Pharmacokinetics, Patient

JINAN, China, May 31, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting.

Key Points: 
  • JINAN, China, May 31, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting.
  • Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, were accepted in the Poster Session.
  • Two of the posters focus on the latest clinical research progress of Qilu Pharmaceutical's QL1706 in extensive-stage small cell lung cancer (ES-SCLC) and advanced hepatocellular carcinoma (HCC).
  • These findings support further investigation of QL1706 plus bevacizumab for first-line treatment of advanced HCC in a phase III clinical trial.

The Golf Coaches Association of America and Nicklaus Companies Extend Long-term Relationship Recognizing Top NCAA Golfers

Retrieved on: 
Tuesday, May 30, 2023
Nicklaus Design, PALM, NCAA, Golden Bear, Memorial Tournament, Life, Marketing, NJCAA, GCAA, Golf Coaches Association of America, Mentorship, Golf, II, Jack Nicklaus, Ohio State University, III, NAIA, Tutoring

NORMAN, Okla. and PALM BEACH GARDENS, Fla., May 30, 2023 /PRNewswire/ -- The Golf Coaches Association of America (GCAA) and the Nicklaus Companies, founded by Jack Nicklaus, are extending their successful relationship honoring the top collegiate golfers.

Key Points: 
  • NORMAN, Okla. and PALM BEACH GARDENS, Fla., May 30, 2023 /PRNewswire/ -- The Golf Coaches Association of America (GCAA) and the Nicklaus Companies, founded by Jack Nicklaus, are extending their successful relationship honoring the top collegiate golfers.
  • Under the agreement, the GCAA is licensed to use the trademarked Jack Nicklaus name with the program to honor college golfers.
  • "The Nicklaus Companies is proud to be associated with the GCAA and collegiate golf, which remains a very important part of both the game and the Jack Nicklaus legacy," Howard Milstein, Executive Chairman of the Nicklaus Companies, said.
  • Established in 1958, the Golf Coaches Association of America (GCAA) is the professional organization of men's collegiate golf coaches.

Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Retrieved on: 
Tuesday, May 30, 2023
PAH, NDA, Janssen, Pulmonary hypertension, Patient, Pulmonary circulation, Tadalafil, Janssen Pharmaceuticals, III, Johnson & Johnson, WHO, ESC, FDA, Orthostatic hypertension, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Constriction, Food, World Health Organization, Pharmaceutical industry

RARITAN, N.J., May 30, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of an investigational single tablet combination therapy of macitentan 10mg and tadalafil 40mg (M/T STCT) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) in adult patients with WHO functional class (FC) II-III.1 The application is based on positive data from the Phase 3 A DUE study, which met its primary endpoint and demonstrated that M/T STCT significantly improved pulmonary hemodynamics (blood flow through pulmonary blood vessels) versus macitentan and tadalafil monotherapies in this PAH patient population.

Key Points: 
  • "Today's submission builds on our decades-long commitment to address patient needs and bring forward medicines with the potential to offer an improved standard of PAH care."
  • Currently, this requires patients to take multiple pills as no single tablet that combines two or more PAH-specific pathways is available for these patients.3
    The NDA is based on late-breaking data from the Phase 3 A DUE study, which met its co-primary endpoints, demonstrating marked pulmonary hemodynamic improvement.
  • The safety profile of M/T STCT was consistent with the safety profile of the individual components, macitentan and tadalafilii,iii.
  • The open label arm of the A DUE study is ongoing.

Glancy Prongay & Murray LLP Announce Pendency and Settlement of Class Action for All Persons and Entities that Purchased or Otherwise Acquired American Depositary Shares of Tenaris S.A. During the Period Between May 1, 2014, and December 5, 2018, Inclusiv

Retrieved on: 
Monday, May 29, 2023
Agreement, Prejudice, Lawsuit, American depositary receipt, Clerk, Person, Class Action, Federal Rules of Civil Procedure, Settlement, District court, Release, Action, Notice, Motion, Hearing, Leading Counsel, Certification, Court, Post office box, United States Senate Judiciary Subcommittee on Federal Courts, Oversight, Agency Action and Federal Rights, ARE, Summons, Claim, Counsel, III, Generic drug, Insurance, Allocation, Defendant, Tenaris

Please read this notice carefully, your rights will be affected by a class action lawsuit pending in this court.

Key Points: 
  • Please read this notice carefully, your rights will be affected by a class action lawsuit pending in this court.
  • YOU ARE ALSO NOTIFIED that Lead Plaintiffs in the Action have reached a proposed settlement of the Action for $9,500,000 in cash (the "Settlement"), that, if approved, will resolve all claims in the Action.
  • If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund.
  • You may also obtain copies of the Notice and Claim Form by contacting the Claims Administrator at In re Tenaris Securities Litigation, c/o A.B.

EQS-News: ams-OSRAM AG: Convocation of the Annual General Meeting 2023

Retrieved on: 
Saturday, May 27, 2023
Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Communication, Person, Ams-OSRAM, Article, Chairperson, Annual general meeting, Supervisory board, Mass meeting, Language, Aktiengesellschaft, Assembly, III, Proxy, Exercise, Works council, General Data Protection Regulation, Disclosure, European, Chapter Three, GDPR, PDF, File, Maquoketa Company–Clinton Machine Company Administration Building, AG, Woman, Shareholder, Reproduction, Address, Employment, ISIN, Bias, Financial adviser, Auction, Security (finance), Holding company, Property management, Insurance

Proxies must be received at one of the aforementioned addresses no later than June 21, 2023, 4:00 p.m., Vienna time, unless they are handed over on the day of the General Meeting when registering for the General Meeting.

Key Points: 
  • Proxies must be received at one of the aforementioned addresses no later than June 21, 2023, 4:00 p.m., Vienna time, unless they are handed over on the day of the General Meeting when registering for the General Meeting.
  • Shareholders may exercise their rights at the General Meeting in person even after granting a proxy.
  • The Supervisory Board mandates of Yen Yen Tan and Brian M. Krzanich will expire at the end of the upcoming Annual General Meeting.
  • The Chairperson may impose, particularly in the beginning but also during the General Meeting, general and individual restrictions on time allowed for speaking or asking questions.

BitNile.com and Ed Carpenter Racing Commemorate 107th Running of the Indianapolis 500 With Sweepstakes and Virtual Brickyard Driving Event

Retrieved on: 
Friday, May 26, 2023
Metaverse, IndyCar, Indianapolis Motor Speedway, Conor Daly, Chevrolet, Conor, VOID, DC, Google Analytics, IndyCar Series, Platform, Indy, 107th Grey Cup, NTT, Winner, III, Auction

Ed Carpenter Racing will field three BitNile.com Chevrolets in the 107th running of the Indianapolis 500.

Key Points: 
  • Ed Carpenter Racing will field three BitNile.com Chevrolets in the 107th running of the Indianapolis 500.
  • Starting in the fifth row is Ed Carpenter in the No.
  • 20 BitNile.com Chevrolet for a drive on a full-size replica of the Indianapolis Motor Speedway , where they will have a first-person virtual experience of racing at full speed around the track.
  • Those accurately selecting the 2023 Indy 500 victor will receive 100,000 Nile Tokens for use on the Platform.

Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma

Retrieved on: 
Thursday, May 25, 2023
Neutropenia, Translation, Clinical Science (journal), International, Probability, ASH, Senior, SCR, AE, Diarrhea, Regeneron Pharmaceuticals, Progression-free survival, CRS, Multiple myeloma, Food, Aes, B-cell maturation antigen, Medicine, B cell, Arthralgia, Associate, Cough, MD Anderson Cancer Center, ASCO, MRD, Fatigue, Death, Kaplan–Meier estimator, American Society of Clinical Oncology, Patient, Cytokine release syndrome, University, Anemia, Annual general meeting, FDA, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Society, III, ORR, BCMA, ISS, Disease, Pharmaceutical industry, Hematology

TARRYTOWN, N.Y., May 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data from two Phase 2 expansion dose cohorts evaluating investigational linvoseltamab (formerly REGN5458) in patients with heavily pre-treated, relapsed/refractory (R/R) multiple myeloma. The results will be shared in an oral session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the LINKER-MM1 trial will form the basis of planned submissions to regulatory authorities, including to the U.S. Food and Drug Administration (FDA) later this year. Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.

Key Points: 
  • Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.
  • “Treatment with linvoseltamab at the recommended 200 mg dose in the LINKER-MM1 trial demonstrated impressive efficacy, with rapid, deep and durable responses in patients with multiple myeloma that’s highly refractory to standard therapies.
  • In the U.S., linvoseltamab has been granted Fast Track Designation for multiple myeloma by the FDA.
  • Linvoseltamab is currently under clinical development, and its safety and efficacy have not been fully evaluated by any regulatory authority.